Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5
Open Access
- 1 January 2023
- journal article
- review article
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 16, 107-127
Abstract
Introduction: The 2016 World Health Organization Classification (WHO) of Tumors of the Central Nervous System (CNS) represented a major change. It recommended an “integrated diagnosis” comprising histologic and molecular information facilitating a more precise diagnosis of specific CNS tumors. Its goal was to provide greater diagnostic precision and reproducibility resulting in more clinical relevance and predictive value, ultimately leading to better patient care. Advances in molecular classification, mostly resulting from DNA methylation array profiling of CNS tumors, were occurring at a very rapid pace and required more rapid integration into clinical practice. Methods: cIMPACT-NOW updates and other recent papers plus salient features of 2021 WHO CNS5 in this comprehensive write-up were reviewed. Results: CNS tumor classification needs to be updated at a rapid pace and mechanisms put into place to guide diagnosticians and clinicians in the interim period if major changes in the classification of tumor types came to light. Recognizing the need to integrate these into clinical practice more rapidly and without inordinate delay, the International Society of Neuropathology (ISN) 2016 sponsored an initiative called cIMPACT-NOW. Discussion and/or Conclusion: Goal of cIMPACT-NOW was to provide clarification regarding contentious issues arising in the wake of the 2016 WHO CNS update as well as report new advancements in molecular classification of CNS tumors and new tumor entities emerging as a result of these advancements. cIMPACT-NOW updates: It thus laid the foundation for the 5th edition of the WHO Classification of CNS tumors (2021 WHO CNS 5). We have discussed cIMPACT updates in detail in this review. In addition, molecular diagnostics including DNA methylation-based classification of CNS tumors and the practical use of molecular classification in the prognostication and treatment of CNS tumors is discussed. Finally, the salient features of the new CNS tumor classification are summarized.Keywords
This publication has 102 references indexed in Scilit:
- International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and GradingBrain Pathology, 2014
- Epigenomic alterations define lethal CIMP-positive ependymomas of infancyNature, 2014
- Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistanceNature Genetics, 2013
- Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomasNature Genetics, 2013
- PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant GlioblastomaBrain Pathology, 2013
- Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomasActa Neuropathologica, 2012
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasActa Neuropathologica, 2012
- Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa EpendymomaCancer Cell, 2011
- Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohortsJournal of Negative Results in BioMedicine, 2011
- A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator ChemotherapyCancer Research, 2006